Calliditas Therapeutics AB - A - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
CALT Nasdaq 2834 https://www.calliditas.se/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Calliditas Therapeutics AB - A

Calliditas to participate in upcoming investor conferences - Mar 31st, 2023 3:24 pm
3 Supercharged Stocks Near 52-Week Highs That Could Keep Climbing - Mar 19th, 2023 10:24 am
Calliditas Plans To File For Complete FDA Approval For Rare Kidney Disease Drug After Positive Phase 3 Data - Mar 13th, 2023 5:15 pm
Calliditas Announces Primary Endpoint Successfully Met in Phase 3 NefIgArd Trial Evaluating Nefecon® in IgA Nephropathy - Mar 13th, 2023 3:15 am
Analyst Sits On Fence While Initiating Calliditas Citing 'Near-Term Opportunity But Longer-Term Questions' - Mar 1st, 2023 9:33 pm
Calliditas - Year-End Report, 2022 - Feb 23rd, 2023 6:41 am
Calliditas Receives Conditional Marketing Authorization from UK MHRA for Kinpeygo in IgA nephropathy - Feb 2nd, 2023 8:46 am
Number of shares and votes in Calliditas Therapeutics - Jan 31st, 2023 7:22 am
New Strong Sell Stocks for January 6th - Jan 6th, 2023 12:41 pm
China CDE/NMPA Recommends Priority Review for Nefecon for the Treatment of Primary IgA Nephropathy - Dec 30th, 2022 8:03 am
Calliditas CEO acquires shares through the exercise of Calliditas' warrant program 2019/2022 - Dec 21st, 2022 3:08 am
Calliditas Therapeutics announces license agreement with Viatris to register and commercialize specialty therapy for IgA nephropathy in Japan - Dec 13th, 2022 8:04 am
Calliditas to host fireside chat with its China commercial partner, Everest Medicines - Dec 9th, 2022 7:10 am
Calliditas' partner Everest Medicine's New Drug Application for Nefecon is accepted by the China NMPA - Nov 15th, 2022 7:45 am
Calliditas Therapeutics: Interim Report Q3, 2022 - Nov 14th, 2022 6:11 am
Key Opinion Leader Fireside Chat with Professor Richard Lafayette on the US IgAN Treatment Landscape - Nov 7th, 2022 8:15 am
Aurinia (AUPH) Moves 13.1% Higher: Will This Strength Last? - Oct 21st, 2022 1:12 pm
Calliditas Therapeutics' nomination committee composition for the AGM 2023 - Oct 21st, 2022 8:27 am
Kidney International Publishes Results from NefIgArd Phase 3 Trial Evaluating TARPEYO® (budesonide) in IgA Nephropathy - Oct 19th, 2022 2:09 pm
Calliditas' partner STADA launches the first medicine authorized in the EU for treating primary IgA nephropathy - Sep 20th, 2022 1:29 pm